Group 1 - The company is undergoing a board re-election process as the term of the second board is about to expire, with the third board candidates being nominated [1][2][3] - The candidates for the third board include three non-independent directors and three independent directors, with the independent candidates requiring approval from the Shanghai Stock Exchange before being submitted to the shareholders' meeting [2][3] - The new board members will serve a term of three years starting from the date of approval by the shareholders' meeting [2][3] Group 2 - The second board members have been diligent and contributed positively to the company's operations during their tenure [3] - The company will continue to operate under the current board until the new board is approved by the shareholders [3] Group 3 - The company plans to use up to RMB 4 billion of temporarily idle funds for cash management, focusing on safe and liquid investment products [21][25] - The cash management aims to improve fund utilization efficiency and increase returns while ensuring the company's normal operations and fund safety [23][31] - The board and supervisory committee have approved this cash management plan, which will be submitted for shareholder approval [32][33] Group 4 - The company is proposing to cancel its supervisory board and transfer its responsibilities to the audit committee of the board, in line with recent regulatory changes [78][79] - The company will revise its articles of association to reflect these changes, including the removal of references to the supervisory board [78][81]
杭州安旭生物科技股份有限公司 关于董事会换届选举的公告